Human herpesvirus 6 (HHV-6) is a T-lymphotropic virus that was first isolated from patients seropositive for human immunodeficiency virus or with lymphoproliferative disorders (22) . HHV-6 infection of humans is common (2, 15, 23) . In infants, the primary infection causes exanthem subitum (roseola infantum) (28) . Despite extensive seroepidemiological studies, little is known about the biology of HHV-6. Lawrence et al. (14) reported on the sequence of a portion of the genome encoding 17 open reading frames. Comparison of the homology and gene organization of HHV-6 with those of other herpesviruses suggested that HHV-6 is related to human cytomegalovirus. Proteins specific for HHV-6-infected human T lymphocytes were preliminarily identified by means of rabbit polyclonal antibodies and mouse monoclonal antibodies (MAbs) (1) . In addition to three glycoprotein species with apparent molecular weights of 102,000, 105,000-82,000, 116,000-64,000-54,000, respectively, these studies detected about 20 proteins ranging in apparent molecular weight from 180,000 to 31,000. The HHV-6-encoded proteins have not been characterized further.
The objectives of our studies are to characterize HHV-6 glycoproteins and to determine their role in the replicative cycle. We report that MAb 2E4 (i) reacts with a glycoprotein with an apparent molecular weight of 100,000 (gplOO), (ii) inhibits the penetration of HHV-6 into susceptible human T lymphocytes, and (iii) prevents the virus-induced cell-cell fusion that results in the formation of large polykaryocytes typical of HHV-6-infected cell cultures.
MATERIALS AND METHODS
Cells and viruses. J-JHAN and HSB-2 cells were grown in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum. Prior to infection, cord blood lymphocytes (CBLs) were grown for 2 days in the same medium containing 5 U of phytohemagglutinin (Sigma Chemical Co.) and 5 U of recombinant interleukin-2 (Boehringer Biochemicals) per ml. X63-Ag8.653 myeloma cells and hybridomas were grown in Iscove medium (Sigma) supplemented with 10% heatinactivated fetal calf serum. HHV-6 isolates U1102 (7) and * Corresponding author.
GS (22) were grown in J-JHAN cells or CBLs and in HSB2 cells, respectively. HHV-6 was concentrated from the culture medium of J-JHAN cells by centrifugation at 100,000 x g for 2 h. Virus titers were determined in J-JHAN cells by limiting dilutions. Infection was determined by scoring for cytopathic effect and for immunofluorescence.
Production of MAbs. HHV-6 (U1102)-infected CBLs were lysed in 0.5% Nonidet P-40-1% sodium deoxycholate in phosphate-buffered saline (PBS), pH 7.4 (buffer A), and centrifuged at 100,000 x g for 1 h. Six-to eight-week-old inbred BALB/c mice were immunized with three intraperitoneal injections of the lysate from about 107 cells in Freund adjuvant. Mouse spleen cells were fused with X63-Ag8.653 myeloma cells, and the hybridoma cells were selected according to standard procedures (6) .
ELISA and IFA. For enzyme-linked immunosorbent assay (ELISA), 96-well plates were coated with lysates of HHV-6-infected or mock-infected J-JHAN cells prepared as described above, diluted in sodium bicarbonate buffer, pH 9.4. Antibody binding was detected by reaction with 1:1,000-diluted rabbit anti-mouse immunoglobulins labeled with horseradish peroxidase. The hybridomas' supernatants that gave an optical density twofold higher against HHV-6-infected cell lysates relative to the mock-infected cell lysates were considered to be positive. For indirect immunofluorescence assay (IFA), the cells were acetone fixed and stained with the hybridoma supernatant or with MAb 2E4 or 2D10 by means of fluorescein isothiocyanate-conjugated rabbit anti-mouse immunoglobulins. MAb 2D10 reacts with HHV-6 gpll2 (7a).
Labeling of cells and SDS-PAGE. HHV-6 (U1102)-infected CBLs were labeled with [35S]methionine (1, 300 Ci/mmol; Radiochemical Centre, Amersham, England) at concentrations of 50 ,uCi/ml of medium containing 1/20 of the usual concentration of unlabeled methionine for labelings of 6 to 12 h and of 500 ,uCi/ml of medium containing no unlabeled methionine for pulse-chase experiments. Labeling with 2-D-[3H]glucosamine (33 Ci/mmol; Radiochemical Centre) was with medium containing 100 ,uCi of the radioactive sugar per ml of medium containing 0.5 mg of glucose per ml. For immunoprecipitations, cells were lysed in 1% Nonidet P-40-1% sodium deoxycholate in PBS containing io-5 M each tolylsulfonyl phenylalanyl chloromethyl ketone and atosyl-L-lysine chloromethyl ketone and centrifuged at 100,000 x g for 1 h. The lysate was incubated with mouse serum or MAb, and the immunoprecipitates were collected with protein A-Sepharose beads as described previously (24) . Samples were subjected to polyacrylamide gel electrophoresis (PAGE) in sodium dodecyl sulfate (SDS)-8.5% polyacrylamide gels cross-linked with N-N'-diallyltartardiamide. The gels were fixed in 10% acetic acid-20% isopropanol and soaked in Amplify (Radiochemical Centre). Dried gels were exposed to Kodak X-Omat film for fluorography.
HHV-6 infectivity neutralization. J-JHAN cells were infected with an HHV-6 preparation that had been preincubated with 10 uninfected CBLs. The hybridomas positive in the three tests were cloned twice. MAb 2E4 precipitated from lysates of HHV-6-infected CBLs a major polypeptide with an apparent molecular weight in denaturing polyacrylamide gels of 100,000 (Fig. 1A, lane c) . The antibody also precipitated other polypeptides in minor quantities; the most prominent were 80,000 and 32,500 in apparent molecular weight. Comparison of the relative amounts of proteins immunoprecipitated by the hyperimmune mouse serum and by MAb 2E4 suggested that the 100,000-molecular-weight polypeptide recognized by MAb 2E4 was present in large amounts in HHV-6-infected cells (compare lanes a and c in Fig. 1A Intracellular localization of gplOO. The intracellular localization of gplOO was studied by IFA analysis of HHV-6-infected J-JHAN or CBLs. In acetone-fixed cells, the staining localized to patches on the plasma membranes and distributed diffusely to the cytoplasm (Fig. 3A and B) ; sometimes a polarized mass was manifest (Fig. 3A) .
Immunoreactivity of MAb 2E4 to HHV-6 (GS). An IFA with MAb 2E4 was performed on HSB-2 cells infected with HHV-6 (GS) (22) to investigate whether gplOO is present in independent isolates of HHV-6. The staining distribution was very similar to that observed with J-JHAN or CBLs infected with HHV-6 (U1102) (Fig. 3C) . The results indicate that gplOO is conserved in two independent isolates of HHV-6 and maintains similar immunologic reactivity.
MAb 2E4 neutralizes virion infectivity. The next series of experiments shows that MAb 2E4 neutralizes HHV-6 infectivity both in the presence and in the absence of complement. A concentrated virus preparation was preincubated with 1:10-fold serial dilutions of MAb 2E4 (ascites fluid) in the presence or in the absence of complement. J-JHAN cells were infected with the preincubated virus preparation and scored daily for the appearance of HHV-6-specific cytopathic effect and of infected cells detectable by IFA with MAb 2D10. As illustrated in Fig. 4 , preincubation of with MAb 2E4 in either the presence or absence of complement completely abolished HHV-6 infectivity. simplex virus (HSV) glycoprotein D (gD) (21) . Under the same experimental conditions in which MAb 2E4 completely abolished HHV-6 infectivity, MAbs 2D10 and HD1 failed to display any neutralizing activity (data not shown). These results indicate that HHV-6 gplOO is part of the virion envelope and suggest that it participates in the entry of HHV-6 into J-JHAN cells.
MAb 2E4 inhibits HHV-6 penetration into J-JHAN cells. For HSVs and for many other viruses, exposure of cells to virus at 4°C results in virus attachment to cells but does not lead to virus entry into the cells. To determine the effect of MAb 2E4 on HHV-6 penetration, HHV-6 was allowed to adsorb to J-JHAN cells at 4°C in the absence of MAb 2E4. Unabsorbed virus was removed, and MAb 2E4 was then added and allowed to bind at 4°C to cells carrying attached virus for 3 h. Unbound antibody was removed. Cells were incubated at 37°C and scored daily for cytopathic effect and for appearance of infected cells. In this experiment, MAb 2E4 was present only from the end of virus adsorption to cells and during shift-up of cells to 37°C. Figures SA and B show that MAb 2E4 inhibited HHV-6 infection when present during virus entry into cells. The extent of virus penetration into cells during the 7-h interval of virus adsorption to cells and of antibody binding at 4°C was insignificant, as assessed in cultures exposed to PBS at pH 3 (13) at the end of the MAb binding (Fig. 5C) . The results indicate that the MAb inhibited virus penetration into cells. The experiments were repeated three times with different batches of ascites fluids. Virus penetration was almost completely prevented in two experiments and highly reduced (about 75%) but not completely blocked in a third. Control experiments were performed on replicate cultures by using either MAb 2D10 against HHV-6 gpll2 or MAb HD1 to HSV gD. These antibodies had no effect on HHV-6 penetration into J-JHAN cells (data not shown).
MAb 2E4 blocks HHV-6-induced polykaryocyte formation.
Cells infected by HHV-6 undergo a typical cytopathic effect characterized by large polykaryocytes (7, 26) . The results of this series of experiments show that gplOO plays an essential role in the HHV-6-induced cell-to-cell fusion that results in the formation of large polykaryocytes. HHV-6-infected J-JHAN cells were incubated with medium without MAb 2E4. At 6 h postinfection, MAb 2E4 was added to a set of replicate cultures and incubation was continued. Cultures were scored for the appearance of syncytia at 2, 3, and 3.5 days after infection, at which time the experiment was terminated. In control cultures incubated in the absence of MAb 2E4, small syncytia were detected at 2 days after infection and became progressively larger. As shown in Fig.  6 , they were virtually absent in cultures incubated in the presence of MAb 2E4. The MAb specifically reduced syncytium formation and not the progression of infection, since in cultures exposed to the MAb and in control (nonexposed) cultures, the percentages of fluorescent cells were very similar.
DISCUSSION
The key findings reported here are as follows. (i) The HHV-6 protein reactive with MAb 2E4 is a glycoprotein. Since the apparent molecular weight of the major polypeptide immunoprecipitated by MAb 2E4 is 100,000, we designated the glycoprotein gplOO. gplOO undergoes posttranslational processing, and very likely a proteolytic cleavage generates a glycosylated polypeptide with an apparent molecular weight of 80,000 and a minor component of approximately 32,500.
(ii) MAb 2E4 reacted by immunofluorescence with two independent isolates of HHV-6, U1102 (7) and GS (22) , suggesting that the epitope recognized by the antibody and, by extension, the glycoprotein is conserved in different strains.
(iii) MAb 2E4 inhibits the penetration of HHV-6 into J-JHAN cells.
(iv) MAb 2E4 inhibits the formation of the large polykaryocytes typical of HHV-6-infected cells.
The ability of MAb 2E4 to inhibit the initiation of infection and cell-cell fusion suggest that gplOO plays a role in these activities. sions were subsequently substantiated by genetic analyses. Therefore, it is convenient to compare the properties of MAb 2E4 with those of antibodies to HSV glycoproteins. Of the seven well-characterized glycoproteins encoded by HSV, three are essential for virus growth in cell culture (3, 5, 16) , whereas the genes for the other four are deletable (17) (18) (19) . The three essential glycoproteins, gB, gD, and gH, are all involved in virus entry into cells (3-5, 8, 9, 11, 16) . gB and gH are highly conserved, and homologs to these glycoproteins are encoded by all of the herpesviruses known to date. By contrast, gD is present in only some members of the Alphaherpesviridae subfamily. On the basis of its neutralizing activities, MAb 2E4 resembles neutralizing antibodies against HSV gD and gH, which inhibit both virus penetration into cells and cell-cell fusion (11, 20) , and differs from neutralizing antibodies against HSV gB, which inhibit virus penetration (12) but do not affect polykaryocyte formation (20) . Whereas for small viruses, such as influenza virus and human immunodeficiency virus, a single glycoprotein mediates the functions of virus entry into the cells and of cell-cell fusion (10, 25, 27) , herpesviruses specify several glycoproteins, and virus entry into the cells and polykaryocyte formation consist of a cascade of events which involve the participation of several glycoproteins. For HHV-6, even the number of glycoproteins encoded by the virus remains to be established. Current studies clearly identify gplOO as one glycoprotein involved in the initiation of HHV-6 infection and in syncytium formation. To determine the precise role of this glycoprotein, further studies aimed at elucidating how many HHV-6 glycoproteins are involved in these processes, and conceivably involving a genetic approach, are needed.
